These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8845497)

  • 21. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The importance of dose: lymphomas as a model of chemosensitive malignancies.
    Bronchud MH
    Eur J Cancer; 1993; 29A Suppl 5():S17-22. PubMed ID: 8260261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The role of autologous bone marrow transplantation in cancer treatment].
    Harada M
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):2989-97. PubMed ID: 2823720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Principles of treatment of hemoblastoses under ambulatory conditions].
    Polonskaia EN; Vinogradova IuE; Lobanova NA; Iudina NI; Korovina VI
    Ter Arkh; 1976; 48(8):54-60. PubMed ID: 828780
    [No Abstract]   [Full Text] [Related]  

  • 26. The third UCH High Dose Meeting.
    Chopra R
    Bone Marrow Transplant; 1994 Mar; 13(3):317-9. PubMed ID: 7911049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
    Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
    Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical phase I studies in oncology and hematology. Concepts, implementation and ethical considerations].
    Hanauske AR
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():68-70. PubMed ID: 8692122
    [No Abstract]   [Full Text] [Related]  

  • 29. [Phase II study of mitoxantrone for hematologic malignancies].
    Ueoka H; Ueno K; Yamane T; Toyoda K; Endo H; Nishihara R; Takahashi I; Ohnoshi T; Kitajima K; Kimura I
    Gan To Kagaku Ryoho; 1983 Nov; 10(11):2399-402. PubMed ID: 6639101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer.
    Mainwaring PN; Gore ME
    Anticancer Drugs; 1995 Oct; 6 Suppl 5():29-41. PubMed ID: 8845493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensification therapy for acute nonlymphoblastic leukemia in adults.
    Glucksberg H; Cheever MA; Farewell VT; Fefer A; Thomas ED
    Cancer; 1983 Jul; 52(2):198-205. PubMed ID: 6344977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and II study of AMSA in childhood tumours.
    Goldman A; Malpas JS
    Cancer Chemother Pharmacol; 1982; 9(1):53-6. PubMed ID: 6958393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The importance of dose and schedule in cancer chemotherapy: breast cancer.
    Leonard RC
    Anticancer Drugs; 1995 Oct; 6 Suppl 5():17-27. PubMed ID: 8845492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors.
    Savarese DM; Hsieh C; Stewart FM
    J Clin Oncol; 1997 Aug; 15(8):2981-95. PubMed ID: 9256143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
    Long GD; Negrin RS; Hoyle CF; Kusnierz-Glaz CR; Schriber JR; Blume KG; Chao NJ
    Cancer; 1995 Sep; 76(5):860-8. PubMed ID: 8625190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
    Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P;
    Eur J Cancer; 2007 Jan; 43(2):258-70. PubMed ID: 17182241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies.
    Ohtsu T; Sai T; Oka M; Sugai Y; Tobinai K
    Jpn J Clin Oncol; 1991 Oct; 21(5):360-5. PubMed ID: 1753416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity.
    Armstrong DK
    Oncologist; 2004; 9(1):33-42. PubMed ID: 14755013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with rituximab in benign and malignant hematologic disorders in children.
    Giulino LB; Bussel JB; Neufeld EJ;
    J Pediatr; 2007 Apr; 150(4):338-44, 344.e1. PubMed ID: 17382107
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.